Ocuphire licenses Nyxol to FamyGen/Viatris for $35M upfront plus milestones and royalties

Opus Genetics, Inc.

Ocuphire receives $35M upfront; FamyGen funds Nyxol development through FDA approvals.
Up to $130M in milestones; first $10M on FDA approval for mydriasis reversal expected in 2023.
Tiered double-digit royalties on worldwide net sales through 2040.
Viatris to commercialize Nyxol globally; Ocuphire retains rights outside licensed territory.
Cash position extended into 2025, supporting presbyopia/NVD trials and APX3330 retina program.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Opus Genetics, Inc. entered into License and Collaboration Agreement with FamyGen Life Sciences, Inc. valued at upfront cash payment of $35 million; potential additional payments of up to $130 million in the aggr (effective 2022-11-06).

Action: entry
Agreement: license
Counterparty: FamyGen Life Sciences, Inc.
Value: upfront cash payment of $35 million; potential additional payments of up to $130 million in the aggr
Effective: 2022-11-06

Exact text from the filing

On November 6, 2022, Ocuphire Pharma, Inc. (“ Ocuphire ”) entered into a License and Collaboration Agreement (the “ License Agreement ”) with FamyGen Life Sciences, Inc. (“ Famy ”), pursuant to which Ocuphire granted Famy an exclusive, perpetual, sub-licensable license to develop, manufacture, import, export and commercialize (i) Nyxol for treating (a) reversal of mydriasis, (b) night vision disturbances or dim light vision, and (c) presbyopia, and (ii) Nyxol and low dose pilocarpine for treating presbyopia (together, the “ Products ”) worldwide except for certain countries and jurisdictions in Asia (the “ Territory ”).

View on SEC.gov

182 material agreements filed in the last 30 days. Browse all material agreements →

Opus Genetics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-22-040303

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.